跳至主要内容
临床试验/EUCTR2018-002144-85-BE
EUCTR2018-002144-85-BE进行中(未招募)1 期

A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease - Galliarde

AbbVie Deutschland0 个研究点目标入组 240 人开始时间: 2019年4月24日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Adult male or female subjects, 30 years of age or older at the time of screening, with a diagnosis of idiopathic PD that is levodopa-responsive.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 120
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 120

排除标准

  • Subjects judged by the investigator to be adequately controlled by current therapy, that don't have recognizable/identifiable Off and On states (motor fluctuations), and have less than 2.5 hours of Off time per day.

研究者

发起方
AbbVie Deutschland

相似试验